Dittlau Katarina Stoklund, Chandrasekaran Abinaya, Freude Kristine, Van Den Bosch Ludo
Department of Neurosciences, Experimental Neurology, and Leuven Brain Institute, KU Leuven - University of Leuven, Leuven, Belgium.
Laboratory of Neurobiology, VIB Center for Brain & Disease Research, Leuven, Belgium.
Bio Protoc. 2024 Feb 20;14(4):e4936. doi: 10.21769/BioProtoc.4936.
Astrocytes are increasingly recognized for their important role in neurodegenerative diseases like amyotrophic lateral sclerosis (ALS). In ALS, astrocytes shift from their primary function of providing neuronal homeostatic support towards a reactive and toxic role, which overall contributes to neuronal toxicity and cell death. Currently, our knowledge on these processes is incomplete, and time-efficient and reproducible model systems in a human context are therefore required to understand and therapeutically modulate the toxic astrocytic response for future treatment options. Here, we present an efficient and straightforward protocol to generate human induced pluripotent stem cell (hiPSC)-derived astrocytes implementing a differentiation scheme based on small molecules. Through an initial 25 days, hiPSCs are differentiated into astrocytes, which are matured for 4+ weeks. The hiPSC-derived astrocytes can be cryopreserved at every passage during differentiation and maturation. This provides convenient pauses in the protocol as well as cell banking opportunities, thereby limiting the need to continuously start from hiPSCs. The protocol has already proven valuable in ALS research but can be adapted to any desired research field where astrocytes are of interest. Key features • This protocol requires preexisting experience in hiPSC culturing for a successful outcome. • The protocol relies on a small molecule differentiation scheme and an easy-to-follow methodology, which can be paused at several time points. • The protocol generates >50 × 10 astrocytes per differentiation, which can be cryopreserved at every passage, ensuring a large-scale experimental output.
星形胶质细胞在诸如肌萎缩侧索硬化症(ALS)等神经退行性疾病中的重要作用日益受到认可。在ALS中,星形胶质细胞从其提供神经元稳态支持的主要功能转变为具有反应性和毒性的作用,这总体上导致了神经元毒性和细胞死亡。目前,我们对这些过程的了解并不完整,因此需要在人类背景下建立高效且可重复的模型系统,以理解并通过治疗手段调节毒性星形胶质细胞反应,为未来的治疗选择提供依据。在此,我们展示了一种高效且直接的方案,用于生成基于小分子分化方案的人诱导多能干细胞(hiPSC)来源的星形胶质细胞。在最初的25天里,hiPSC分化为星形胶质细胞,并在接下来的4周多时间里使其成熟。hiPSC来源的星形胶质细胞在分化和成熟的每个传代阶段都可进行冷冻保存。这为实验方案提供了便利的暂停点以及细胞冻存的机会,从而减少了持续从hiPSC开始的需求。该方案已在ALS研究中证明了其价值,但可适用于任何对星形胶质细胞感兴趣的研究领域。关键特性 • 该方案需要有hiPSC培养的前期经验才能成功实施。 • 该方案依赖于小分子分化方案和易于遵循的方法,可在多个时间点暂停。 • 每次分化可产生>50×10的星形胶质细胞,且每个传代阶段都可冷冻保存,确保了大规模的实验产出。